Numerous clinical trials evaluate levodopa and related therapeutic regimens across Phase 1 through Phase 4, focusing predominantly on Parkinson's disease, levodopa-induced dyskinesias, and central nervous system movement disorders. These investigations are sponsored by diverse entities ranging from pharmaceutical companies—such as AbbVie, NeuroDerm Ltd., and PharmaTher Inc.—to academic institutions like Stanford University. Across this global clinical portfolio, study statuses encompass completed, active non-recruiting, suspended, and upcoming protocols that are not yet recruiting.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07151378 | RECRUITING | PARKINSON DISEASE (Disorder) |
University Hospital Tuebingen |
2025-10-27 | PHASE3 |
| NCT07793461 | NOT_YET_RECRUITING | Parkinson's Disease |
Beth Israel Deaconess Medical Center |
2027-07 | PHASE4 |
| NCT06891781 | NOT_YET_RECRUITING | Parkinson Disease, Idiopathic |
Newronika |
2026-08 | |
| NCT07781696 | NOT_YET_RECRUITING | Freezing of Gait Symptoms in Parkinson Disease |
Iahn Cajigas |
2026-09 | |
| NCT06013956 | RECRUITING | Parkinson Disease |
David Escobar |
2023-08-29 | PHASE4 |
| NCT05285683 | RECRUITING | Chronic Pain |
University of Rochester |
2024-01-31 | PHASE2 |
| NCT04735627 | RECRUITING | Parkinson Disease |
University of California, San Diego |
2021-12-07 | |
| NCT07725562 | RECRUITING | Parkinson Disease (PD) |
Zhejiang Vimgreen Pharmaceuticals, Ltd. |
2026-07-17 | PHASE2; PHASE3 |
| NCT07647913 | NOT_YET_RECRUITING | Parkinson Disease(PD) |
McMaster University |
2026-09-01 | |
| NCT07432958 | RECRUITING | Parkinson Disease |
Appello Pharmaceuticals, Inc. |
2026-02-25 | PHASE2 |
| NCT06234995 | RECRUITING | Parkinson Disease |
Emory University |
2021-08-09 | PHASE4 |
| NCT06570824 | RECRUITING | Dyskinesia, Drug-Induced; Parkinson Disease |
Danish Research Centre for Magnetic Resonance |
2024-08-22 | |
| NCT06075771 | RECRUITING | Anhedonia; Depression |
Emory University |
2023-11-21 | PHASE4 |
| NCT06316232 | RECRUITING | Freezing of Gait; Parkinson Disease |
IRCCS Istituto delle Scienze Neurologiche di Bologna |
2023-10-10 | PHASE4 |
| NCT06785298 | RECRUITING | Parkinson Disease |
Tanta University |
2024-12-10 | PHASE2; PHASE3 |
| NCT07229664 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-10 | PHASE2; PHASE3 |
| NCT07229651 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-10 | PHASE2; PHASE3 |
| NCT07246278 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-20 | PHASE1; PHASE2 |
| NCT06113640 | RECRUITING | Parkinson Disease |
Mostafa Bahaa |
2023-11-05 | PHASE2; PHASE3 |
| NCT06831500 | RECRUITING | Multi-system Atrophy - Parkinsonian Type; Orthostatic Hypotension, Dysautonomic; Parkinson Disease |
Julien Bally |
2025-07-18 | PHASE1; PHASE2 |
| NCT07375693 | ENROLLING_BY_INVITATION | Parkinson Disease |
Bangladesh Medical University |
2026-02-17 | PHASE2 |
| NCT07442591 | RECRUITING | Healhty |
Shanghai WD Pharmaceutical Co., Ltd. |
2026-03-24 | PHASE1 |
| NCT07001150 | RECRUITING | Parkinson Disease |
Tanta University |
2025-05-10 | PHASE2 |
| NCT06722729 | ACTIVE_NOT_RECRUITING | Parkinson Disease |
Kissei Pharmaceutical Co., Ltd. |
2024-12-16 | PHASE2 |
| NCT06772220 | RECRUITING | Parkinson&Amp;#39;s Disease |
Oregon Health and Science University |
2024-03-05 | |
| NCT06365515 | UNKNOWN | Hormonal Changes; Menstrual Cycle |
University Hospital Tuebingen |
2024-05 | |
| NCT07444892 | COMPLETED | Diabetic Retinopathy |
Emory University |
2022-04-18 | PHASE2 |
| NCT06765668 | RECRUITING | Parkinson Disease |
Impax Laboratories, LLC |
2025-02-12 | PHASE4 |
| NCT06596876 | COMPLETED | Parkinson's Disease |
Jiangsu HengRui Medicine Co., Ltd. |
2024-11-06 | PHASE3 |
| NCT05471609 | COMPLETED | Healthy Volunteers |
University of Minnesota |
2025-06-12 | EARLY_PHASE1 |
| NCT06954662 | COMPLETED | Parkinson Disease, Idiopathic |
UConn Health |
2025-05-22 | EARLY_PHASE1 |
| NCT07055958 | ACTIVE_NOT_RECRUITING | Parkinson Disease |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2024-12-29 | PHASE3 |
| NCT05463367 | ACTIVE_NOT_RECRUITING | Opioid Use; Opioid Dependence; Opioid-use Disorder; Narcotic Use; Back Pain; Back Injuries; Chronic Pain; Chronic Low-back Pain; Pain, Chronic; Pain;Back Low;Chronic; Pain, Back |
Northwestern University |
2021-01-01 | PHASE2 |
| NCT06587217 | COMPLETED | Parkinsonian Signs in Older Persons |
University of Michigan |
2024-10-29 | PHASE1; PHASE2 |
| NCT05094011 | Not yet recruiting | Idiopathic Parkinson''s Disease |
Taiwan Mitochondrion Applied Technology Co. Ltd. |
2025-03-01 | Phase 1 |
| NCT05781711 | COMPLETED | Parkinson Disease |
Tanta University |
2023-01-06 | PHASE2 |
| NCT05297201 | COMPLETED | Parkinson Disease; Dyskinesia, Medication-Induced |
Celon Pharma SA |
2021-11-02 | PHASE2 |
| NCT06115538 | UNKNOWN | Parkinson Disease; Treatment Adherence |
Ankara Ataturk Sanatorium Training and Research Hospital |
2023-10-01 | PHASE4 |
| NCT05962957 | COMPLETED | Parkinson Disease |
Mostafa Bahaa |
2023-08-07 | PHASE2 |
| NCT04218526 | COMPLETED | Parkinson Disease |
Jonathan Jagid |
2020-04-27 | |
| NCT06284629 | Not yet recruiting | Parkinson Disease |
Rigshospitalet Denmark|Odense University Hospital|Zealand University Hospital |
2024-09-01 | Not Applicable |
| NCT05262348 | WITHDRAWN | Parkinson Disease |
Newronika |
2022-08 | |
| NCT03735901 | ACTIVE_NOT_RECRUITING | Acute Stroke; Stroke Rehabilitation |
University Hospital, Basel, Switzerland |
2019-06-14 | PHASE3 |
| NCT05558189 | Not yet recruiting | Parkinson Disease |
Stanford University |
2024-08-20 | Not Applicable |
| NCT05959044 | UNKNOWN | Parkinson Disease |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2023-04-16 | PHASE2 |
| NCT06236230 | UNKNOWN | Parkinson Disease |
Second Affiliated Hospital of Soochow University |
2023-11-15 | PHASE4 |
| NCT06339034 | Not yet recruiting | Parkinson Disease |
State University of New York at Buffalo|The Cure Parkinson''s Trust |
2024-06 | Phase 1|Phase 2 |
| NCT06219915 | COMPLETED | Parkinsonian Signs in Older Persons |
University of Michigan |
2024-03-15 | PHASE1; PHASE2 |
| NCT04821830 | COMPLETED | Parkinson Disease |
University of Michigan |
2020-02-12 | PHASE4 |
| NCT05119075 | COMPLETED | Parkinson Disease |
Insel Gruppe AG, University Hospital Bern |
2021-11-10 | |
| NCT06614153 | COMPLETED | Parkinson's Disease |
Jiangsu HengRui Medicine Co., Ltd. |
2023-05-16 | PHASE2 |
| NCT04542499 | COMPLETED | Parkinson Disease |
AbbVie |
2020-09-23 | PHASE3 |
| NCT06180720 | UNKNOWN | Healthy |
The Affiliated Hospital of Qingdao University |
2023-12-20 | PHASE1 |
| NCT06432309 | COMPLETED | Parkinson Disease; Effect of Drug |
University Hospital of Ferrara |
2022-07-01 | |
| NCT04952194 | UNKNOWN | Parkinson Disease |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-01-01 | PHASE4 |
| NCT05752240 | UNKNOWN | Parkinson Disease |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2022-03-10 | |
| NCT04912115 | SUSPENDED | Dyskinesias; Movement Disorders; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations |
PharmaTher Inc. |
2021-10-05 | PHASE2 |
| NCT05087914 | WITHDRAWN | Acute Pain; Bunionectomy; Toe Fusion |
Northwestern University |
2021-11-01 | PHASE2 |
| NCT05795088 | UNKNOWN | Parkinson Disease |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2022-06-16 | |
| NCT04147949 | UNKNOWN | Parkinson Disease; Dyskinesia, Medication-Induced; L-Dopa Causing Adverse Effects in Therapeutic Use |
VistaGen Therapeutics, Inc. |
2022-08 | PHASE2 |
| NCT06037590 | COMPLETED | Parkinson; Parkinson Disease; Parkinson's Disease and Parkinsonism |
PureIMS B.V. |
2023-09-25 | PHASE1 |
| NCT04723147 | COMPLETED | Depression; Anhedonia |
Emory University |
2021-01-29 | PHASE4 |
| NCT04052776 | COMPLETED | Spinal Cord Injuries; Drug Effect |
Centre Hospitalier Universitaire Vaudois |
2020-09-11 | PHASE1 |
| NCT05976737 | UNKNOWN | Healthy |
The Affiliated Hospital of Qingdao University |
2023-08-17 | PHASE1 |
| NCT04742348 | WITHDRAWN | Alcohol Drinking |
University of Washington |
2023-02 | PHASE4 |
| NCT05312632 | COMPLETED | Parkinson Disease |
Eisai Korea Inc. |
2022-04-05 | PHASE4 |
| NCT05487300 | COMPLETED | Parkinson Disease; Orthostatic Hypotension |
University of Utah |
2022-05-11 | PHASE2; PHASE3 |
| NCT04990284 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2021-11-29 | PHASE4 |
| NCT05094050 | COMPLETED | Parkinson's Disease |
AbbVie |
2022-01-18 | PHASE1 |
| NCT05683925 | COMPLETED | Parkinson Disease; Gait Disorders, Neurologic |
University Medical Centre Ljubljana |
2022-09-01 | |
| NCT05148884 | COMPLETED | Medication-Induced Dyskinesia |
Neurolixis SAS |
2021-11-09 | PHASE2 |
| NCT04978597 | COMPLETED | Parkinson |
Bial - Portela C S.A. |
2021-05-31 | PHASE3 |
| NCT05492019 | UNKNOWN | Parkinson Disease |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2022-07-01 | PHASE2 |
| NCT05036473 | COMPLETED | Parkinson Disease |
Shanghai WD Pharmaceutical Co., Ltd. |
2021-11-11 | PHASE2 |
| NCT04082715 | WITHDRAWN | Chronic Back Pain |
Second Affiliated Hospital of Wenzhou Medical University |
2019-10 | PHASE2 |
| NCT05435729 | COMPLETED | Levodopa-induced Dyskinesia; Parkinson's Disease |
Sumitomo Pharma Co., Ltd. |
2022-05-31 | PHASE1 |
| NCT05083260 | COMPLETED | Parkinson Disease |
BioVie Inc. |
2022-01-04 | PHASE1; PHASE2 |
| NCT02542696 | COMPLETED | Parkinson Disease |
Sumitomo Pharma America, Inc. |
2015-08-31 | PHASE3 |
| NCT03111485 | COMPLETED | Parkinson's Disease; Obstructive Sleep Apnea |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2017-05-24 | PHASE4 |
| NCT06021756 | UNKNOWN | Levodopa-Induced Dyskinesia; Parkinson's Disease |
University of Arizona |
2019-07-28 | PHASE1 |
| NCT04821687 | COMPLETED | Parkinson Disease |
SK Chemicals Co., Ltd. |
2021-06-17 | PHASE4 |
| NCT04778176 | COMPLETED | Parkinson's Disease |
SynAgile Corporation |
2021-06-16 | PHASE2 |
| NCT03929068 | COMPLETED | Amyotrophic Lateral Sclerosis; Motor Neuron Disease |
Washington University School of Medicine |
2019-05-13 | PHASE1 |
| NCT05523791 | COMPLETED | Parkinson Disease |
Ospedale Generale Di Zona Moriggia-Pelascini |
2022-01-01 | |
| NCT05116813 | TERMINATED | Parkinson Disease; Dyskinesia, Drug-Induced; Dyskinesias |
Addex Pharma S.A. |
2021-10-25 | PHASE2; PHASE3 |
| NCT04857359 | TERMINATED | Parkinson Disease; Dyskinesia, Drug-Induced; Dyskinesias |
Addex Pharma S.A. |
2021-08-06 | PHASE2; PHASE3 |
| NCT05901350 | COMPLETED | Parkinson Disease; Visual Impairment |
Qilu Hospital of Shandong University |
2019-06-01 | |
| NCT05250141 | COMPLETED | Bioequivalence |
Laboratorios Andromaco S.A. |
2022-02-14 | PHASE1 |
| NCT04590612 | UNKNOWN | Parkinson Disease; Depression |
Western University, Canada |
2021-01 | |
| NCT04650217 | TERMINATED | Depressive Disorder |
New York State Psychiatric Institute |
2021-10-07 | PHASE4 |
| NCT05128175 | COMPLETED | Parkinson Disease |
Shanghai WD Pharmaceutical Co., Ltd. |
2021-10-29 | PHASE1 |
| NCT02480803 | COMPLETED | Parkinson's Disease |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-12-19 | PHASE4 |
| NCT06275633 | COMPLETED | Parkinson Disease; Medication; UPDRS; Motor Function; Cognitive Impairment; Depression; Impulsive; Levodopa |
University Hospital Bispebjerg and Frederiksberg |
2019-03-19 | |
| NCT00660673 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2009-11-13 | PHASE3 |
| NCT04493320 | TERMINATED | Depression; Cognitive Impairment; Gait Impairment |
New York State Psychiatric Institute |
2021-02-10 | PHASE4 |
| NCT04380142 | COMPLETED | Parkinson's Disease (PD) |
AbbVie |
2020-10-19 | PHASE3 |
| NCT04054960 | UNKNOWN | Parkinson Disease |
Western University, Canada |
2019-09 | |
| NCT03881371 | COMPLETED | Parkinson Disease |
Zambon SpA |
2019-08-01 | PHASE3 |
| NCT03391882 | COMPLETED | Motor OFF Episodes Associated With Parkinson's Disease |
Sumitomo Pharma America, Inc. |
2018-12-19 | PHASE3 |
| NCT03065192 | COMPLETED | Idiopathic Parkinson's Disease; Parkinson's Disease; Basal Ganglia Disease; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Nervous System Diseases; Neurodegenerative Diseases; Parkinsonian Disorders |
Neurocrine Biosciences |
2017-05-11 | PHASE1 |
| NCT03670953 | COMPLETED | Parkinson's Disease (Disorder) |
Impax Laboratories, LLC |
2018-11-06 | PHASE3 |
| NCT04591535 | UNKNOWN | Parkinson Disease |
Hong Kong WD Pharmaceutical Co., Limited |
2020-09-28 | PHASE1 |
| NCT02589340 | TERMINATED | Parkinson's Disease; Dyskinesias; Movement Disorders |
Oregon Health and Science University |
2016-01 | PHASE1 |
| NCT04173845 | UNKNOWN | Levodopa-Induced Dyskinesia |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2019-09-01 | |
| NCT02873351 | WITHDRAWN | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2019-09 | PHASE2 |
| NCT02601586 | COMPLETED | Parkinson Disease |
University Hospital, Toulouse |
2016-09 | PHASE2; PHASE3 |
| NCT04513340 | UNKNOWN | Parkinson Disease |
Hong Kong WD Pharmaceutical Co., Limited |
2020-08-13 | PHASE1 |
| NCT03922711 | TERMINATED | Parkinson Disease |
Prilenia |
2019-05-22 | PHASE2 |
| NCT03197493 | COMPLETED | Macula; Degeneration; Retina |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-08-01 | PHASE2 |
| NCT02549092 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2015-10-26 | PHASE3 |
| NCT03703570 | COMPLETED | Parkinson's Disease |
Kyowa Kirin Co., Ltd. |
2018-09-29 | PHASE2 |
| NCT03419806 | COMPLETED | Parkinson Disease |
Vastra Gotaland Region |
2018-02-16 | PHASE1 |
| NCT03023059 | COMPLETED | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-05-02 | PHASE2 |
| NCT02513485 | COMPLETED | Depression |
Emory University |
2015-10-09 | PHASE4 |
| NCT03162874 | COMPLETED | Parkinson Disease |
Prexton Therapeutics |
2017-07-04 | PHASE2 |
| NCT01973543 | COMPLETED | Parkinson's Disease |
Neurocrine Biosciences |
2013-10 | PHASE1 |
| NCT03022318 | COMPLETED | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-05-02 | PHASE2 |
| NCT02615873 | UNKNOWN | Parkinson's Disease |
Intec Pharma Ltd. |
2016-07 | PHASE3 |
| NCT03451500 | TERMINATED | Age Related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2018-07-01 | PHASE2 |
| NCT03205956 | COMPLETED | Parkinson's Disease |
Kevin J. Black, MD |
2017-10-19 | PHASE1 |
| NCT02799381 | COMPLETED | Parkinson's Disease (PD) |
AbbVie |
2017-02-09 | PHASE3 |
| NCT04236921 | COMPLETED | Other |
Riverside Pharmacueticals Corporation |
2019-07-15 | PHASE1 |
| NCT02726386 | ACTIVE_NOT_RECRUITING | Parkinson's Disease |
NeuroDerm Ltd. |
2016-05-04 | PHASE2 |
| NCT03761004 | COMPLETED | Healthy Volunteers |
Hong Kong WD Pharmaceutical Co., Limited |
2019-01-14 | PHASE1 |
| NCT02605434 | UNKNOWN | Parkinson's Disease |
Intec Pharma Ltd. |
2016-03 | PHASE3 |
| NCT03887884 | COMPLETED | Parkinson's Disease |
Acorda Therapeutics |
2019-03-05 | PHASE1 |
| NCT03599726 | COMPLETED | Parkinson Disease |
Oregon Health and Science University |
2018-07-30 | EARLY_PHASE1 |
| NCT03331848 | WITHDRAWN | Parkinson Disease |
Prexton Therapeutics |
2018-01-15 | PHASE2 |
| NCT03235037 | COMPLETED | Angelman Syndrome |
Bennett Lavenstein |
2013-11-26 | |
| NCT03576638 | UNKNOWN | Parkinson Disease |
Intec Pharma Ltd. |
2018-07 | PHASE2 |
| NCT03462043 | WITHDRAWN | Parkinson |
NeuroDerm Ltd. |
2018-04-10 | PHASE3 |
| NCT03119636 | UNKNOWN | Parkinson's Disease |
Chinese Academy of Sciences |
2017-05 | PHASE1; PHASE2 |
| NCT02782481 | WITHDRAWN | Parkinson's Disease |
NeuroDerm Ltd. |
2016-08 | PHASE3 |
| NCT03354455 | COMPLETED | Dyskinesia, Drug-Induced; Parkinson Disease |
Danish Research Centre for Magnetic Resonance |
2017-08-01 | |
| NCT02744391 | COMPLETED | Major Depressive Disorder; Dysthymia; Depression Not Otherwise Specified; Decreased Processing Speed; Decreased Gait Speed |
New York State Psychiatric Institute |
2016-08-24 | PHASE4 |
| NCT02657681 | COMPLETED | Dyskinesia, Medication-Induced; Parkinson's Disease |
Fundación de investigación HM |
2015-10 | PHASE2 |
| NCT02769793 | COMPLETED | Parkinson Disease |
Seoul National University Hospital |
2015-06 | PHASE4 |
| NCT02847442 | COMPLETED | Parkinson's Disease With Wearing-off Motor Fluctuations |
Bial - Portela C S.A. |
2016-11-23 | PHASE4 |
| NCT03496870 | COMPLETED | Parkinson Disease |
Neurocrine Biosciences |
2018-02-08 | PHASE1 |
| NCT02560389 | COMPLETED | Stress Disorder, Post Traumatic |
University of Wisconsin, Madison |
2016-03 | PHASE4 |
| NCT02242487 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2015-03 | PHASE3 |
| NCT01663935 | TERMINATED | Albinism; Oculocutaneous Albinism |
University of Wisconsin, Madison |
2012-10-17 | PHASE2 |
| NCT02764125 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2016-04-08 | PHASE2 |
| NCT02202551 | COMPLETED | Dyskinesia; Levodopa Induced Dyskinesia (LID); Parkinson's Disease (PD) |
Adamas Pharmaceuticals, Inc. |
2014-07 | PHASE3 |
| NCT03051607 | TERMINATED | Idiopathic Parkinson Disease |
Biotie Therapies Inc. |
2017-04-10 | PHASE3 |
| NCT02453386 | TERMINATED | Idiopathic Parkinson's Disease |
Biotie Therapies Inc. |
2015-07 | PHASE3 |
| NCT02469090 | COMPLETED | Parkinson Disease, Off Episodes |
Sumitomo Pharma America, Inc. |
2015-06-18 | PHASE3 |
| NCT01951105 | COMPLETED | Sub-acute Back Pain |
Northwestern University |
2015-02-24 | PHASE4 |
| NCT03000569 | COMPLETED | Parkinson Disease |
Biogen |
2016-11-30 | PHASE2 |
| NCT03140956 | COMPLETED | Parkinson Disease |
Orion Corporation, Orion Pharma |
2017-04-19 | PHASE1 |
| NCT03055936 | COMPLETED | Healthy Volunteers |
Orion Corporation, Orion Pharma |
2017-02-21 | PHASE1 |
| NCT02837640 | UNKNOWN | Retinitis Pigmentosa |
Beirut Eye Specialist Hospital |
2016-06 | PHASE2 |
| NCT02439125 | UNKNOWN | Parkinson's Disease; Dyskinesia |
Amarantus BioScience Holdings, Inc. |
2015-05 | PHASE2 |
| NCT02641054 | COMPLETED | Idiopathic Parkinson Disease |
CleveXel Pharma |
2016-02 | PHASE2 |
| NCT02785978 | COMPLETED | Parkinson Disease; Healthy Volunteers |
Institut de Myologie, France |
2016-06 | |
| NCT02452606 | UNKNOWN | Parkinson Disease; Sleep Disorders |
Asan Medical Center |
2015-03 | |
| NCT02352363 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2015-03 | PHASE3 |
| NCT03531060 | COMPLETED | Parkinson Disease |
Integrative Research Laboratories AB |
2016-11-08 | PHASE1; PHASE2 |
| NCT02337751 | COMPLETED | Parkinson's Disease |
Takeda |
2015-07-10 | PHASE3 |
| NCT02386475 | COMPLETED | Stroke |
Hospital de Granollers |
2015-01 | PHASE4 |
| NCT02346630 | WITHDRAWN | Stroke |
Ross D. Zafonte, MD |
2015-03 | PHASE4 |
| NCT01393457 | COMPLETED | Cocaine Dependence |
The University of Texas Health Science Center, Houston |
2011-06 | PHASE2 |
| NCT02080819 | COMPLETED | Cocaine Dependence |
Virginia Commonwealth University |
2014-02 | PHASE2 |
| NCT00223691 | COMPLETED | Autonomic Failure; Orthostatic Hypotension |
Vanderbilt University |
2002-03 | PHASE1 |
| NCT02577523 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2015-12-29 | PHASE2 |
| NCT02240030 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2014-11 | PHASE3 |
| NCT02807675 | COMPLETED | Parkinson's Disease |
Acorda Therapeutics |
2016-06 | PHASE1 |
| NCT02337764 | COMPLETED | Parkinson's Disease |
Takeda |
2015-02-03 | PHASE3 |
| NCT02337738 | COMPLETED | Parkinson's Disease |
Takeda |
2015-01-27 | PHASE2; PHASE3 |
| NCT02337725 | COMPLETED | Parkinson's Disease |
Takeda |
2015-02-07 | PHASE3 |
| NCT00715520 | COMPLETED | Stroke |
Emory University |
2007-04 | |
| NCT00607451 | TERMINATED | Levodopa-induced Dyskinesia |
Neurim Pharmaceuticals Ltd. |
2008-03 | PHASE1; PHASE2 |
| NCT02812394 | COMPLETED | Parkinson Disease |
Acorda Therapeutics |
2016-06 | PHASE1 |
| NCT02153645 | TERMINATED | Parkinson's Disease; Levodopa Induced Dyskinesias (LID) |
Adamas Pharmaceuticals, Inc. |
2014-08-18 | PHASE3 |
| NCT02153632 | TERMINATED | Parkinson's Disease; Levodopa Induced Dyskinesia (LID) |
Adamas Pharmaceuticals, Inc. |
2014-07-30 | PHASE3 |
| NCT02633839 | COMPLETED | Smoking |
Acorda Therapeutics |
2015-12 | PHASE1 |
| NCT02274766 | COMPLETED | Dyskinesia; Levodopa-Induced Dyskinesia (LID); Parkinson's Disease (PD) |
Adamas Pharmaceuticals, Inc. |
2014-10 | PHASE3 |
| NCT02633007 | COMPLETED | Asthma |
Acorda Therapeutics |
2015-12 | PHASE1 |
| NCT01937169 | UNKNOWN | Restless Legs Syndrome |
Tel-Aviv Sourasky Medical Center |
2014-01 | |
| NCT02439203 | COMPLETED | Parkinson's Disease; Levodopa Induced Dyskinesia (LID) |
Bukwang Pharmaceutical |
2015-05 | PHASE2 |
| NCT02741947 | COMPLETED | Parkinson Disease |
IRCCS San Raffaele Roma |
2014-04 | PHASE4 |
| NCT01636037 | COMPLETED | Schizophrenia |
Centre for Addiction and Mental Health |
2012-09 | PHASE2 |
| NCT02136914 | COMPLETED | Dyskinesia; Levodopa Induced Dyskinesia (LID); Parkinson's Disease |
Adamas Pharmaceuticals, Inc. |
2014-05 | PHASE3 |
| NCT02073773 | COMPLETED | Ischaemic Stroke |
Singapore General Hospital |
2014-01 | PHASE3 |
| NCT02554734 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2015-08 | PHASE1 |
| NCT02763137 | COMPLETED | Parkinson Disease |
IRCCS San Raffaele Roma |
2014-07-30 | PHASE2 |
| NCT03333369 | COMPLETED | Healthy; Schizotypal Personality |
University of Zurich |
2014-05-15 | EARLY_PHASE1 |
| NCT01484184 | COMPLETED | Spinal Cord Injury |
Nordic Life Science Pipeline Inc. |
2013-07 | PHASE1; PHASE2 |
| NCT01281475 | COMPLETED | Angelman Syndrome |
Wen-Hann Tan |
2011-01 | PHASE2; PHASE3 |
| NCT02448914 | COMPLETED | Parkinson's Disease |
LobSor Pharmaceuticals AB |
2015-05 | PHASE1 |
| NCT02005029 | COMPLETED | Parkinson's Disease; Levodopa |
Virginia Commonwealth University |
2013-04 | |
| NCT01883505 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2014-01-06 | PHASE2 |
| NCT02486432 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2015-04 | PHASE1 |
| NCT02096601 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2014-08-11 | PHASE1 |
| NCT01960842 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2013-10 | PHASE3 |
| NCT01736176 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2013-03 | PHASE3 |
| NCT01767129 | COMPLETED | Dyskinesia; Parkinson's Disease |
Avanir Pharmaceuticals |
2013-10-16 | PHASE2 |
| NCT02312232 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2014-11 | PHASE1 |
| NCT01840423 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2013-05 | PHASE1 |
| NCT01683253 | COMPLETED | Impulse Control Disorder |
Sandoz |
2012-11 | PHASE4 |
| NCT01176435 | COMPLETED | Albinism |
University of Minnesota |
2010-09 | PHASE2 |
| NCT01646255 | COMPLETED | Idiopathic Parkinson's Disease |
UCB Pharma |
2012-07 | PHASE3 |
| NCT01688089 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2012-09 | PHASE1 |
| NCT01470859 | COMPLETED | Idiopathic Parkinson's Disease |
Huashan Hospital |
2011-12 | |
| NCT01468012 | COMPLETED | Cocaine Dependence |
New York State Psychiatric Institute |
2014-07 | PHASE2; PHASE3 |
| NCT01937078 | COMPLETED | Dyskinesia |
University Health Network, Toronto |
2011-04 | PHASE2 |
| NCT02116465 | COMPLETED | Fasted State |
Desitin Arzneimittel GmbH |
2014-03 | PHASE1 |
| NCT01777555 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2013-04 | PHASE2 |
| NCT01190813 | COMPLETED | Amblyopia |
Jaeb Center for Health Research |
2010-09 | PHASE3 |
| NCT01556165 | COMPLETED | Parkinson's Disease |
H. Lundbeck A/S |
2012-04 | PHASE3 |
| NCT01568073 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2011-03 | PHASE3 |
| NCT01577992 | COMPLETED | Pain Threshold; Multiple System Atrophy |
University Hospital, Toulouse |
2011-12-01 | |
| NCT01479530 | COMPLETED | Parkinson's Disease |
H. Lundbeck A/S |
2011-12 | PHASE3 |
| NCT01736891 | COMPLETED | Parkinson´s Disease |
Chongqing Fortune Pharmaceutical Co., Ltd. |
2011-11 | PHASE3 |
| NCT01397422 | COMPLETED | Dyskinesia; Levodopa Induced Dyskinesia; Parkinson's Disease |
Adamas Pharmaceuticals, Inc. |
2011-07 | PHASE2; PHASE3 |
| NCT01411137 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2011-08 | PHASE3 |
| NCT01725802 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2012-12-16 | PHASE1 |
| NCT01486628 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2012-04-30 | PHASE1 |
| NCT01617135 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2012-05 | PHASE2 |
| NCT01283594 | COMPLETED | Parkinson's Disease |
Biotie Therapies Inc. |
2011-03 | PHASE2; PHASE3 |
| NCT00918177 | COMPLETED | Parkinson's Disease |
Intec Pharma Ltd. |
2009-07 | PHASE2 |
| NCT00360568 | COMPLETED | Dyskinesias; Parkinson's Disease; Severe Motor Fluctuations |
AbbVie (prior sponsor, Abbott) |
2009-06 | PHASE3 |
| NCT01515410 | COMPLETED | Parkinson's Disease; Motor Fluctuations |
Depomed |
2012-01 | PHASE2 |
| NCT01479127 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2011-10 | PHASE2 |
| NCT01227655 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2011-03 | PHASE3 |
| NCT01528592 | COMPLETED | Parkinson's Disease |
Northwestern University |
2011-06 | |
| NCT01218425 | COMPLETED | Dopamine Activity; Episodic Memory Consolidation; Response Preparation |
Maastricht University Medical Center |
2010-11 | |
| NCT00335153 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2008-01 | PHASE3 |
| NCT01268891 | COMPLETED | Parkinson's Disease |
H. Lundbeck A/S |
2011-01 | PHASE3 |
| NCT01437293 | COMPLETED | Cocaine Abuse |
New York State Psychiatric Institute |
2010-08 | PHASE1 |
| NCT00218023 | COMPLETED | Cocaine Abuse; Cocaine-Related Disorders |
The University of Texas Health Science Center, Houston |
2006-03 | PHASE2 |
| NCT01429077 | COMPLETED | Nonfluent Aphasia; Stroke |
Shirley Ryan AbilityLab |
2007-10 | PHASE2; PHASE3 |
| NCT01336088 | COMPLETED | Parkinson's Disease |
Addex Pharma S.A. |
2011-04 | PHASE2 |
| NCT01191944 | COMPLETED | Parkinson Disease |
Boehringer Ingelheim |
2010-08 | PHASE3 |
| NCT01130493 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2010-05 | PHASE3 |
| NCT02170376 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2011-09 | PHASE1 |
| NCT00627640 | COMPLETED | Idiopathic Parkinson's Disease |
Newron Pharmaceuticals SPA |
2009-02 | PHASE3 |
| NCT00713583 | COMPLETED | Cocaine Dependence |
The University of Texas Health Science Center, Houston |
2008-01 | PHASE2 |
| NCT01113320 | COMPLETED | Parkinson's Disease |
Newron Pharmaceuticals SPA |
2010-04 | PHASE2 |
| NCT01229332 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2011-01 | PHASE1; PHASE2 |
| NCT00357994 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2009-01 | PHASE3 |
| NCT00660387 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2009-12 | PHASE3 |
| NCT01296464 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2011-02 | PHASE2 |
| NCT00758368 | WITHDRAWN | Parkinson's Disease |
Oregon Health and Science University |
2009-03 | PHASE2 |
| NCT01023282 | COMPLETED | Parkinson's Disease; Tolerability |
NeuroSearch A/S |
2009-11 | PHASE1 |
| NCT00141518 | COMPLETED | Advanced Idiopathic Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2006-03 | PHASE4 |
| NCT00632762 | COMPLETED | Parkinson's Disease |
University Hospital, Toulouse |
2007-11 | PHASE4 |
| NCT00914134 | COMPLETED | Parkinson's Disease |
University of Helsinki |
2009-04 | PHASE4 |
| NCT00552474 | COMPLETED | Parkinson Disease; Movement Disorders |
Abbott Medical Devices |
2005-10 | |
| NCT01103011 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2010-04 | PHASE1 |
| NCT00634556 | COMPLETED | Tourette Syndrome |
Washington University School of Medicine |
2006-02 | PHASE1 |
| NCT00957918 | COMPLETED | Parkinson's Disease |
Neuraltus Pharmaceuticals, Inc. |
2009-10 | PHASE1; PHASE2 |
| NCT01484990 | COMPLETED | Parkinson Disease |
AbbVie |
2010-04 | PHASE1 |
| NCT01026428 | COMPLETED | Idiopathic Parkinson's Disease |
Newron Pharmaceuticals SPA |
2009-09 | PHASE1; PHASE2 |
| NCT02169414 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2010-02 | PHASE1 |
| NCT01568047 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2010-02 | PHASE2 |
| NCT00829439 | COMPLETED | Angelman Syndrome |
Boston Children's Hospital |
2009-01 | PHASE1 |
| NCT00845000 | COMPLETED | Parkinson Disease |
Merck Sharp & Dohme LLC |
2009-04-21 | PHASE1 |
| NCT01286935 | COMPLETED | Parkinson's Disease |
Newron Pharmaceuticals SPA |
2007-08 | PHASE3 |
| NCT01519284 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-11 | PHASE1 |
| NCT01070628 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2009-12 | PHASE1 |
| NCT01568034 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2009-04 | PHASE2 |
| NCT00601978 | WITHDRAWN | Parkinson's Disease |
Novartis Pharmaceuticals |
2008-08 | PHASE4 |
| NCT00906828 | COMPLETED | Parkinson Disease |
Uppsala University |
2008-10 | PHASE4 |
| NCT01533077 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-03 | PHASE1 |
| NCT01327261 | COMPLETED | Healthy Volunteers |
University of Buenos Aires |
2009-08 | PHASE4 |
| NCT00789672 | COMPLETED | Amblyopia |
Jaeb Center for Health Research |
2009-01 | PHASE2 |
| NCT00941265 | COMPLETED | Aphasia |
University Hospital, Geneva |
2007-02 | |
| NCT01533116 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-03 | PHASE1 |
| NCT00869791 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2008-11 | PHASE2 |
| NCT02169466 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2009-01 | PHASE1 |
| NCT00605553 | COMPLETED | Parkinson's Disease |
Biotie Therapies Inc. |
2008-04 | PHASE2 |
| NCT00642356 | TERMINATED | Parkinson's Disease |
Novartis |
2008-03 | PHASE4 |
| NCT00272688 | COMPLETED | Parkinson Disease |
University Hospital, Akershus |
2006-01 | PHASE4 |
| NCT00438607 | COMPLETED | Parkinson's Disease |
Biogen |
2007-04 | PHASE2 |
| NCT00307450 | COMPLETED | Parkinson's Disease |
Technische Universität Dresden |
2006-03 | PHASE4 |
| NCT00125567 | COMPLETED | Idiopathic Parkinson's Disease |
Orion Corporation, Orion Pharma |
2005-08 | PHASE4 |
| NCT02169453 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2008-10 | PHASE1 |
| NCT02169479 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2008-09 | PHASE1 |
| NCT00558337 | COMPLETED | Parkinson's Disease |
Osmotica Pharmaceutical US LLC |
2007-11 | PHASE2 |
| NCT00099268 | COMPLETED | Parkinson's Disease |
Novartis Pharmaceuticals |
2004-09 | PHASE3 |
| NCT00477802 | TERMINATED | Parkinson Disease |
University of Cincinnati |
2007-05 | PHASE4 |
| NCT02169895 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2008-09 | PHASE1 |
| NCT00590122 | COMPLETED | Parkinson's Disease |
Baylor College of Medicine |
2006-10 | PHASE4 |
| NCT01187966 | COMPLETED | Parkinson's Disease |
Newron Pharmaceuticals SPA |
2007-01 | PHASE3 |
| NCT00153972 | COMPLETED | Parkinson's Disease |
Technische Universität Dresden |
2005-02 | PHASE4 |
| NCT00219284 | COMPLETED | Parkinson's Disease With End of Dose Wearing Off |
Novartis Pharmaceuticals |
2005-01 | PHASE4 |
| NCT00391898 | COMPLETED | Parkinson's Disease |
Novartis |
2006-10 | PHASE4 |
| NCT00888186 | COMPLETED | Parkinson Disease; Dyskinesias |
Uppsala University |
2008-02 | PHASE4 |
| NCT00693862 | COMPLETED | Pharmacokinetics |
Orion Corporation, Orion Pharma |
2006-12 | PHASE1 |
| NCT00360308 | TERMINATED | Parkinson's Disease |
Eisai Limited |
2006-11 | PHASE3 |
| NCT00505622 | TERMINATED | Parkinson's Disease |
Eisai Limited |
2007-07 | PHASE3 |
| NCT00360412 | TERMINATED | Parkinson's Disease |
Eisai Inc. |
2006-10 | PHASE3 |
| NCT00406588 | COMPLETED | Advanced Stage Parkinson's Disease |
Solvay Pharmaceuticals |
2007-03 | PHASE3 |
| NCT00505843 | COMPLETED | Parkinson's Disease |
Merck Sharp & Dohme LLC |
2007-05 | PHASE1 |
| NCT00562198 | TERMINATED | Parkinson´s Disease |
Orion Corporation, Orion Pharma |
2008-01 | PHASE2 |
| NCT00368108 | COMPLETED | Parkinson's Disease |
Eisai Inc. |
2006-08 | PHASE3 |
| NCT00253084 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2005-11 | PHASE2 |
| NCT00218075 | COMPLETED | Cocaine Abuse; Cocaine-Related Disorders |
The University of Texas Health Science Center, Houston |
2000-03 | PHASE2 |
| NCT03103399 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2006-09-26 | PHASE2 |
| NCT00134966 | COMPLETED | Parkinson's Disease |
Novartis |
2005-08 | PHASE3 |
| NCT00462007 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2006-09 | PHASE4 |
| NCT00399477 | COMPLETED | Parkinson's Disease |
Teva Neuroscience, Inc. |
2006-10 | PHASE4 |
| NCT00286897 | COMPLETED | Parkinson's Disease |
Eisai Limited |
2006-02 | PHASE3 |
| NCT00666653 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2003-07 | PHASE1 |
| NCT00134784 | COMPLETED | Parkinson Disease |
Institute for Neurodegenerative Disorders |
2000-04 | PHASE2 |
| NCT00199368 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2004-10 | PHASE3 |
| NCT00692328 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2005-08 | |
| NCT00203957 | COMPLETED | Parkinson's Disease |
University of Chicago |
2005-03 | PHASE3 |
| NCT00102869 | COMPLETED | Cerebrovascular Accident; Aphasia |
University Hospital Muenster |
2005-01 | PHASE4 |
| NCT00129181 | COMPLETED | Parkinson Disease; Parkinsonian Syndrome |
Institute for Neurodegenerative Disorders |
2005-01 | |
| NCT00203177 | COMPLETED | Parkinson's Disease |
Teva Branded Pharmaceutical Products R&D, Inc. |
2001-10 | PHASE3 |
| NCT03097211 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2006-07-17 | PHASE1 |
| NCT03094156 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2006-04-26 | PHASE1 |
| NCT00143026 | COMPLETED | Parkinson's Disease |
Novartis |
2005-07 | PHASE4 |
| NCT00199355 | COMPLETED | Parkinson's Disease |
Kyowa Kirin Co., Ltd. |
2005-04 | PHASE2 |
| NCT02778594 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2005-09 | PHASE1 |
| NCT00199407 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2004-06 | PHASE3 |
| NCT00199420 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2004-07 | PHASE3 |
| NCT02774564 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2005-09 | PHASE1 |
| NCT02834507 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2005-03 | PHASE2 |
| NCT00199394 | COMPLETED | Parkinson's Disease |
Kyowa Kirin Co., Ltd. |
2004-11 | PHASE3 |
| NCT00103805 | COMPLETED | Healthy |
University Hospital Muenster |
2003-03 | PHASE4 |
| NCT00203164 | COMPLETED | Parkinson's Disease |
Teva Branded Pharmaceutical Products R&D, Inc. |
2002-05 | PHASE3 |
| NCT00244387 | COMPLETED | Parkinson Disease, Idiopathic |
UCB Pharma |
2004-03 | PHASE3 |
| NCT01044992 | COMPLETED | Multisystemic Atrophy |
University Hospital, Toulouse |
2002-05 | |
| NCT03091868 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2004-11-03 | PHASE1 |
| NCT00148512 | COMPLETED | Parkinson Disease |
Boehringer Ingelheim |
2003-03 | PHASE2 |
| NCT00144209 | COMPLETED | Restless Legs Syndrome |
Boehringer Ingelheim |
2003-02 | PHASE3 |
| NCT00160576 | COMPLETED | Idiopathic Parkinson Disease |
UCB Pharma |
2003-07 | PHASE2 |
| NCT03091543 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2004-05-04 | PHASE1 |
| NCT00139867 | COMPLETED | Parkinson's Disease |
UCB Pharma |
2004-01 | PHASE3 |
| NCT00812760 | COMPLETED | Retinal Diseases |
Medical University of Vienna |
2001-10 | PHASE4 |
| NCT00456794 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-03 | PHASE2 |
| NCT00955045 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-08 | PHASE2; PHASE3 |
| NCT00456586 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-04 | PHASE2 |
| NCT00203034 | COMPLETED | Parkinson's Disease |
Teva Branded Pharmaceutical Products R&D, Inc. |
2000-05 | PHASE3 |
| NCT02763852 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2001-04 | PHASE1 |
| NCT02763839 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2001-04 | PHASE1 |
| NCT00203060 | COMPLETED | Parkinson's Disease |
Teva Neuroscience, Inc. |
1997-07 | PHASE3 |
| NCT02177357 | COMPLETED | Parkinson Disease |
Boehringer Ingelheim |
1998-11 | PHASE3 |
| NCT00086294 | COMPLETED | Parkinson's Disease; Dyskinesias |
National Institute of Neurological Disorders and Stroke (NINDS) |
2004-06-25 | PHASE2 |
| NCT00291733 | UNKNOWN | Levodopa Induced Dyskinesia |
1st Hospital of Social Security Services |
2006-05 | PHASE2 |
| NCT00006077 | COMPLETED | Parkinson's Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2000-08 | PHASE2 |
| NCT00108667 | COMPLETED | Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2005-04 | PHASE2 |
| NCT00625547 | COMPLETED | Restless Legs Syndrome |
Pfizer |
2003-01 | PHASE3 |
| NCT00004733 | COMPLETED | Parkinson's Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
1998-01 | PHASE3 |
| NCT00296959 | TERMINATED | Parkinson's Disease |
University Health Network, Toronto |
2004-09 | PHASE2 |
| NCT00111371 | UNKNOWN | Dyslexia |
University Hospital Muenster |
2005-01 | PHASE4 |
| NCT01351168 | WITHDRAWN | Parkinson's Disease |
Rush University Medical Center |
PHASE2 | |
| NCT00247247 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2002-12 | PHASE4 |
| NCT00507715 | COMPLETED | Parkinson's Disease, Idiopathic |
Rottapharm Spain |
2006-09 | PHASE1 |
| NCT00432393 | COMPLETED | Nonarteritic Anterior Ischemic Optic Neuropathy |
Shahid Beheshti University of Medical Sciences |
2002-06 | PHASE4 |
| NCT00451633 | WITHDRAWN | Parkinson's Disease |
Eisai Inc. |
2007-03 | PHASE2 |
| NCT00415922 | COMPLETED | Healthy |
Novartis |
2006-07 | PHASE1 |
| NCT00040209 | COMPLETED | Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2002-06 | PHASE2 |
| NCT00415831 | COMPLETED | Healthy |
Novartis |
2006-06 | PHASE1 |
| NCT00102284 | TERMINATED | Healthy |
University Hospital Muenster |
2004-03 | PHASE4 |
| NCT00096720 | COMPLETED | Parkinson Disease; Parkinsonian Syndrome |
Institute for Neurodegenerative Disorders |
2004-02 | PHASE2 |
| NCT00076674 | COMPLETED | Dyskinesias; Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2004-01 | PHASE2 |
| NCT00306124 | UNKNOWN | Alzheimer's Disease; Mild Cognitive Impairment; Healthy |
University Hospital Muenster |
2006-01 | PHASE4 |
| NCT00415740 | COMPLETED | Healthy |
Novartis |
2006-05 | PHASE1 |
| NCT00006337 | COMPLETED | Parkinson's Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2000-10 | PHASE2 |
| NCT00174239 | TERMINATED | Parkinson Disease |
Pfizer |
2004-07 | PHASE4 |
| NCT00089622 | COMPLETED | Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2004-08-04 | PHASE2 |
| NCT00415844 | COMPLETED | Healthy |
Novartis |
2006-06 | PHASE1 |
| NCT00013624 | COMPLETED | Parkinson's Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2001-03 | PHASE2 |
| NCT00009048 | COMPLETED | Parkinson's Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2001-01 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-07-13)
Check the
Levodopa
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.